Abstract: The invention relates to the identification of a biomarker whose abundance in biological sample is changed in subjects with osteoarthritis and/or other ageing-related diseases. The biomarker has applications in the diagnosis of osteoarthritis and/or other ageing-related diseases, in determining the prognosis for an individual diagnosed with osteoarthritis and/or other ageing-related diseases, and in monitoring the efficacy of treatment for osteoarthritis and/or other ageing-related diseases.

Abstract: The present invention relates to the medical field. In a first aspect the present invention relates to novel water soluble cyclodextrin-curcumin complexes having a pharmacological activity, in particular an anti-tumor and/or anti-inflammatory activity, and improved physico-chemical properties. In a second aspect, the present invention relates to a method for preparation of said water soluble curcumin derivatives. The invention further relates in a third aspect to a pharmaceutical composition comprising an effective amount of said water soluble curcumin derivatives. In a fourth aspect, the present invention concerns the use of said water soluble cucumin derivatives as a medicament and the use of said water soluble curcumin derivatives for the preparation of a medicament for the treatment of cancer and inflammatory diseases.

Abstract: The present invention relates to a method and system for the determination of parameters related to the speed of wind that blows near an overhead electrical power line (single or bundle conductors). The parameters include an “effective wind speed” as well as an “effective incident radiation” acting on a power line span. The measurement is made by using the combination of mechanical vibrations and movements/positions in two or three dimensions through sensors in direct link with the power line conductor.

Abstract: The invention provides an in vitro method or assay for the diagnosis of osteochondrosis or prediction of the likelihood of its onset in a terrestrian mammal, comprising measuring the expression level of a marker in a sample obtained from said terrestrian mammal and comparing said expression level to the expression level of said marker measured in a sample obtained from one or more terrestrian mammals of the same species not affected by osteochondrosis, wherein the marker is ApoB-3G, and wherein an increase in the expression level of ApoB-3G is indicative of osteochondrosis. The invention also provides a diagnostic kit for use in said method, which comprises at least one agent, which binds specifically to the product of the gene of the respective marker and which can be used to determine the expression level of said marker, wherein the marker is ApoB-3G.

Abstract: The present application discloses particularly interleukin-8 (IL-8) as a novel biomarker for the prediction, diagnosis, prognosis and/or monitoring of impaired bone fracture healing; and related methods, uses and kits.

Abstract: The present invention relates an organic liquid composition comprising a mixture of a first polymer with a linear polymeric chain having two photoactive groups as endgroup; and a second polymer with a multifunctional polymeric chain having at least three photoactive groups, that can reversibly and repeatedly crosslink to form a solid polymer network wherein said liquid composition been crosslinked by irradiation with at least one wavelength L1 and been uncrosslinked at least locally by irradiating the network with at least one other wavelength L2 in order to repeatedly adjust shape and optical properties of said composition in its crosslinked state. The composition is applicable as a starting material for intraocular lenses and for other lenses and optical elements.

Abstract: New bacterium GC61 belonging to the genus Bifidobacterium, probiotic compositions comprising said bacterium, particularly food products, and use of said bacterium in the treatment of diseases, such as gastrointestinal diseases.

Abstract: The present invention is related to a method to obtain reactive [18F] fluorides in an organic medium suitable for radiolabelling without any azeotropic evaporation step, by the use of a solid phase extraction column containing a modified non-ionic solid support.

Abstract: An object of the invention is to provide a cheap, efficient and polyvalent energy harvesting system able to exploit several energy sources. The invention proposes an energy harvesting system (100) comprising a frame, at least one permanent magnet (101) having a North/South direction, and at least one winding (107, 108) wound according to a winding direction around a core (103a-103b) comprising a high magnetic permeability material, at least said at least one permanent magnet being mounted on the frame to be able to oscillate relatively to the winding, characterized in that the system comprises a magnetic flux divider arranged between said at least one permanent magnet and said at least one winding in order to concentrate the magnetic flux at discrete positions of maximum magnetic flux then forming equilibrium positions where the winding faces one of the said discrete positions of maximum magnetic flux.

Abstract: The invention relates to an amphiphilic block copolymer, to the preparation thereof, and to the use thereof in the form of a self-stabilizing latex. The copolymer has the formula R5O—[—CH2CH2—O—]n—C(?O)—CR3R4—[CH2CR6R7]m—S—C(?S)—S—R1 where: R1 is a straight or branched alkyl group, an alkenyl group having one or more —C?C— bonds, or an alkynyl group having one or more —C?C— bonds, said groups including 8 to 18 carbon atoms; 20?n?100; R3 and R4 each are independently H, an alkyl group with 1 to 4 carbon atoms, or a nitrile group, at least one of R3 and R4 being different than H; R6 is a phenyl group or an alkoxycarbonyl group in which the alkoxy group includes 1 to 8 carbon atoms; R7 is a hydrogen atom or a methyl radical; and 20?m?1000.

Abstract: Method for the manufacture of carbon nanotubes by thermal decomposition of at least one gaseous hydrocarbon (14) in the presence of a solid catalyst in a reactor (4) into which the catalyst is introduced via an inlet lock chamber (17) flushed by an inert gas (21, 22, 25, 26) and from which the carbon nanotubes are withdrawn via an outlet lock chamber (37) which is flushed with a flow of inert gas (39, 40).

Abstract: The invention relates to the use of one or more of protein myoferlin, protein latent-transforming growth factor beta binding protein2, protein transforming growth factor beta induced protein ig-h3, protein asporin, protein tenascin, protein periostin, protein galectin, protein fibronectin, protein prolargin, protein protein-glutamine gamma-glutamyl transferase 2, protein agrin, protein adipocyte enhancer-binding protein 1, protein annexin A6, protein laminin alpha-2 subunit, proteinlaminin subunit alpha-4, protein mimecan, protein Ras-related protein Rap-2b, protein collagen alpha-1 (XIV) chain, protein collagen alpha-3 (VI) chain, protein latent-transforming growth factor beta binding protein 1, protein V type proton ATPase catalytic subunit A, protein laminin alpha-4 and protein transmembrane protein 62 as a biomarker for pancreatic cancer, or a predisposition thereto.

Abstract: The present invention relates to an implant comprising: —a core material comprising polydimethylsiloxane or at least one hydrogel polymer; —a tube encasing said core material comprising an ethylene vinyl acetate polymer or at least one hydrogel polymer; —a sealant for closure of the open ends of said tube comprising polydimethylsiloxane or a mono-, di-, or triacetoxy derivative thereof, or at least one hydrogel polymer; and —at least one active ingredient; wherein said at least one active ingredient is selected from the group comprising celecoxib, sulindac, tamoxifen, oestrogen, oestradiol, ethinyl oestradiol, mestranol, dienogest, norgestrel, levonorgestrel, desogestrel, norgestimate, ethynodiol diacetate, leuprorelin, buserelin, gonrelin, triptorelin, nafarelin, deslorelin, histrelin, and supprelin; and with the proviso that when the sealant is said at least one hydrogelpolymer, the core material comprises polydimethylsiloxane. Furthermore, the invention relates to an implant for use as a medicament.

Abstract: Process for the preparation of a halogenated polymer comprising a controlled radical polymerization step of at least one monomer containing at least one halogen-carbon bond, performed in the presence of an organo-cobalt complex, said polymerization step being further carried out in non-isotherm conditions.

Abstract: It refers to a recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, comprising a deletion in the stem domain, wherein at least one heterologous sequence is inserted in a region selected from the group consisting of regions defined by amino acid position of 108 to 151, 1 to 5, 288 to 293, 43 to 48, 235 to 240, 92 to 97, 31 to 36,or 156 to 161 of SEQ ID NO: 1, with the proviso that, if the heterologous sequence contains five or more consecutive histidines the moiety of the heterologous sequence other than the moiety of five or more consecutive histidines has a minimum length of 11 amino acids; or a variant thereof comprising 1-50 amino acids added, substituted or deleted in SEQ ID NO. 1 and the activity to form oligomers and to bind to lipidic bilayers. It also provides a medicament and vaccine comprising said recombinant polypeptide.

Abstract: A method can be used for treating or reducing likelihood of an influenza A virus-induced disease in a mammal. The method includes administering a polynucleotide to the mammal. Theis polynucleotide includes a gene encoding Mx protein having a TRAF2 and/or a TRAF6 binding domain. The TRAF2 and/or TRAF6 binding domain can be represented by the sequences P-X-Q/E-E, P-X-Q/E-X-X-D, or P-X-E-E-X-E. The TRAF2 and/or TRAF6 binding domain can also be located in the Mx protein in a position which corresponds to the position of the hexapeptide PEEESE in the bovine Mx1 protein or in a position which is up to 20 amino acid residues upstream or downstream of that position.

Abstract: The invention provides the use of a cyclodextrin compound for the manufacturing of a medicament for the treatment or prevention of bronchial inflammatory diseases, particularly for asthma and chronic obstructive pulmonary disease (COPD).

Abstract: The invention relates to a method of analyzing spectral data for the selection of a calibration model, relating spectra of a substance to a physical or chemical parameter of the substance, over a predetermined range of the physical or chemical parameter, comprising the steps: a) capturing spectral data of the substance with respective values of the physical or chemical parameter over the predetermined range, b) creating a plurality of calibration models using the captured spectral data in dependence upon the values of the physical or chemical parameter based on the calibration data using statistical resampling methods, c) calculating tolerance intervals of the results at each reference level for each calibration model, and d) displaying the tolerance intervals at each reference level over the predetermined range for each calibration model.

Abstract: A method to extract out of an aqueous solution, concentrate and/or reformulate [18F] fluorides without any evaporation step wherein the eluting solution is a organic solution having a water content <3%. The solution contains at least: an organic solvent suitable for the subsequent radiolabelling reaction; a first compound (A) which is a molecule containing at least one acidic hydrogen and a second compound (B) which is an organic base sufficiently strong to be able to tear off the acidic hydrogen of the first compound (A) in an acid-base reaction leading to the formation of an organic salt (S).

Abstract: An object of the present invention is to provide a cheap, rapid, controlled, reproducible and polyvalent method for manufacturing a light emitting device with an internal source of light capable of achieving an enhancement in extraction efficiency. The invention proposes a method for manufacturing an optical layer for a light emitting device having an internal source of light and an optical layer separating the internal source of light and an external medium of light diffusion, wherein the method comprises the use of coherent electromagnetic radiation speckle lithography, such as laser speckle lithography, to make a nano/micro texturation on at least one surface of the optical layer.